Tramadol/type-5 cyclic nucleotide phosphodiesterase inhibitor - Aytu BioScience

Drug Profile

Tramadol/type-5 cyclic nucleotide phosphodiesterase inhibitor - Aytu BioScience

Alternative Names: PDE5 inhibitor/tramadol - Aytu BioScience; Tramadol/PDE5 inhibitor - Aytu BioScience; Type-5 cyclic nucleotide phosphodiesterase inhibitor/tramadol - Aytu BioScience; Zertane-ED™; Zertane/PDE5 inhibitor

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ampio Pharmaceuticals
  • Developer Aytu BioScience; Daewoong Pharmaceutical
  • Class Cyclohexanols; Dimethylamines; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Erectile dysfunction; Premature ejaculation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in South Korea (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Premature-ejaculation in South Korea (PO, Tablet)
  • 16 Apr 2015 Rosewind Corporation, Vyrix Pharmaceuticals and Luoxis Diagnostics merged to form Aytu BioScience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top